ArticleFrontiers in immunology2025
Identification and validation of m
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combining bioinformatics and machine learning to analyze and validate sepsis-related cell senescence genes and potential drugs.Renal failure · 2026Article
- Integrative analysis of transcriptome and single-cell sequencing combined with experimental validation identifies biomarkers associated with T cell and senescence in sepsis.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis, a systemic inflammatory response syndrome triggered by infection, is associated with high mortality rates and an increasing global incidence. While Methods: Transcriptomic datasets of sepsis, along with m Results: DPP4 and TXN were identified as key biomarkers, showing higher expression in control and sepsis samples, respectively. The nomogram incorporating these biomarkers demonstrated strong diagnostic potential. Enrichment analysis highlighted their involvement in spliceosome function and antigen processing and presentation. Differential analysis of immune cell types revealed significant correlations between biomarkers and immune cells, such as macrophages and activated dendritic cells. Drug predictions identified gambogenic acid and valacyclovir as potential treatments, which were successfully docked with the biomarkers. Single-cell analysis revealed that the biomarkers were predominantly expressed in CD4 Conclusions: DPP4 and TXN were validated as biomarkers for sepsis, with insights into immune infiltration and therapeutic potential at the single-cell level, offering novel perspectives for sepsis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.